Form 8-K - Current report:
SEC Accession No. 0001193125-25-152652
Filing Date
2025-06-30
Accepted
2025-06-30 16:01:19
Documents
13
Period of Report
2025-06-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d80696d8k.htm   iXBRL 8-K 33945
2 EX-10.1 d80696dex101.htm EX-10.1 472936
  Complete submission text file 0001193125-25-152652.txt   743870

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA dyn-20250627.xsd EX-101.SCH 2847
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE dyn-20250627_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dyn-20250627_pre.xml EX-101.PRE 10811
15 EXTRACTED XBRL INSTANCE DOCUMENT d80696d8k_htm.xml XML 3497
Mailing Address 1560 TRAPELO ROAD WALTHAM MA 02451
Business Address 1560 TRAPELO ROAD WALTHAM MA 02451 (781) 786-8230
Dyne Therapeutics, Inc. (Filer) CIK: 0001818794 (see all company filings)

EIN.: 364883909 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39509 | Film No.: 251091871
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)